Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Rob Jones

- PMLiVE

How COVID-19 has renewed the focus on behaviour change

By Rachel Rowson

- PMLiVE

Making the case for embedding personalised healthcare in secondary care – what can pharma do to help?

By Doina Ionescu

- PMLiVE

Celebrating World Blood Donor Day

Each 14th June World Blood Donor day is celebrated around the world to spread awareness around the importance of giving blood.

Innovative Trials

- PMLiVE

Eli Lilly and Incyte’s Olumiant receives FDA approval for alopecia

The treatment is the first and only systemic medicine for adults with the condition

- PMLiVE

Genomics England will move headquarters to Canary Wharf’s new life sciences hub

The company will join the growing number of healthcare and life sciences-focused organisations currently located in Canary Wharf

- PMLiVE

Happify Health and Almirall launch Claro to support psoriasis patients

The digital wellness app is now available to those with the condition living in the UK, Spain and Italy

- PMLiVE

The future of healthcare professional engagement

By Ilana Scholl

- PMLiVE

90TEN Medical appoints Niamh Mangan as its new managing director

Mangan previously worked at Cello Health Cypher and ApotheCom

- PMLiVE

Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed

Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...

Wilmington Healthcare

- PMLiVE

CureVac to acquire Frame Cancer Therapeutics in €32m deal

The acquisition will advance CureVac’s oncology strategy and offers the potential to develop off-the-shelf and personalised cancer vaccines

- PMLiVE

Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

Both the COVIBOOST and phase 3 VAT02 trials showed the booster was well-tolerated, with favourable safety profiles

- PMLiVE

Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

Both the COVIBOOST and phase 3 VAT02 trials showed the booster was well-tolerated, with favourable safety profiles

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links